CHROMONAR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27NO5
Molecular Weight	361.4321
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)COC1=CC=C2C(OC(=O)C(CCN(CC)CC)=C2C)=C1

InChI

InChIKey=KLOIYEQEVSIOOO-UHFFFAOYSA-N

InChI=1S/C20H27NO5/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3/h8-9,12H,5-7,10-11,13H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C20H27NO5
Molecular Weight	361.4321
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://lekarstwo.ru/en/preparati/carbocromenum.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219

Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Platelet Aggregation (Plug Formation) 5 Target ID: WP1884 Sources: http://www.ncbi.nlm.nih.gov/pubmed/947200	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Coronary artery disease 48 Sources: http://www.ncbi.nlm.nih.gov/pubmed/756818	Primary		Approved 8583	Intensain Approved Use Indications for use: Angina without expressed stenotic process protracted and prolonged attacks, postinfarction period.

Doses

Dose	Population	Adverse events
675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	Disc. AE: Arthralgia... Other AEs: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Arthralgia (22%) Other AEs: Nausea (5%) Vomiting (2.4%) Nervousness (2.4%) Dizziness (5%) Headache (2.4%) Insomnia (2.4%) Malaise (2.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
80 mg single, intravenous Highest studied dose Dose: 80 mg Route: intravenous Route: single Dose: 80 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4956317/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4956317/	Sources: https://pubmed.ncbi.nlm.nih.gov/4956317/

AEs

AE	Significance	Dose	Population
Headache	2.4%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Insomnia	2.4%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Malaise	2.4%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Nervousness	2.4%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Vomiting	2.4%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Arthralgia	22% Disc. AE	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Dizziness	5%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/
Nausea	5%	675 mg 3 times / day multiple, oral Highest studied dose Dose: 675 mg, 3 times / day Route: oral Route: multiple Dose: 675 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/4966194/

PubMed

Title	Date	PubMed
Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins.	2010-01-12	20110890
Protective effects of a coumarin derivative in diabetic rats.	2009-08	19279317
Retinal and systemic pharmacokinetics of the anti-inflammatory drug cloricromene following oral administration in the rat and rabbit.	2007-06	17593009
Enhancement of availability of cloricromene at brain level by a lipophilic prodrug.	2006-07	16805962
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.	2006-04	16572308
Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.	2006-03-24	16584158
Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits.	2006-01-18	16126232
Cloricromene in endotoxemia: role of NF-kappaB.	2004-08	15322736
Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.	2004-07	15233861
In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form.	2004-06-18	15158956
A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat.	2004-04-16	15043989
Preparation and characterization of solid lipid nanoparticles containing cloricromene.	2003-11-13	14612340
Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats.	2003-03	12601047
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.	2002-02-05	11863286
Intradermal injection vs. oral treatment of tinnitus.	2001-10-27	11677863
Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits.	2001-09	11514313
Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level.	2001-04-27	11343695
Protective actions of carbocromene against amitriptyline-induced cardiotoxicity in anesthetized rats.	1986-01	3963932
Cardioprotective effects of carbocromen in awake and anesthetized dogs with amitriptyline poisoning.	1985-07-01	2410706

Patents

Sample Use Guides

In Vivo Use Guide

Inside after food: 0,075 - 0,15 g (1 - 2 tablets) 3 times a day. In more severe cases, to begin receiving 0.15 g 4 times a day, and after improving the dose is reduced to 0.075 g of 3 - 4 times daily. It is noted that the effect of the drug increases (to 10 - 30th day) and lasts a long time. Take in a few weeks or months (up to 6 months).

Route of Administration: Oral

In Vitro Use Guide

In bovine heart mitochondria ho/h-1 ratios in repeated scans increased in presence of carbocromen (20--40 umol/l)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:21:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:21:51 GMT 2025`
Record UNII	R0C9NIE5JJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARBOCROMEN

Preferred Name

English

CHROMONAR

Common Name

English

ACETIC ACID, ((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)-, ETHYL ESTER

Common Name

English

((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)ACETIC ACID ETHYL ESTER

Systematic Name

English

AG-3 FREE BASE

Code

English

carbocromen [INN]

Common Name

English

Carbocromen [WHO-DD]

Common Name

English

A-27053 FREE BASE

Code

English

NSC-110430 FREE BASE

Code

English

CHROMONAR [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C01DX05